- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02716246
Ensaio Clínico de Transferência de Gene Fase I/II/III de scAAV9.U1a.hSGSH
Ensaio Clínico de Transferência de Gene Fase I/II/III de scAAV9.U1a.hSGSH para Mucopolissacaridose (MPS) IIIA
The main objective of this study is to evaluate the efficacy and safety of UX111 for the treatment of MPS IIIA.
Visão geral do estudo
Status
Descrição detalhada
Open-label, single dose, dose-escalation clinical trial of UX111 (scAAV9.U1a.hSGSH) injected intravenously through a peripheral limb vein. A limited course of prophylactic immunomodulatory (IM) therapy will be administered. At approved sites adjuvant IM therapy may be administered to selected participants. The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IM therapy. Not all participants may receive adjuvant IM therapy.
This study was previously posted by Abeona Therapeutics, Inc and was transferred to Ultragenyx in August 2022.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
- Fase 3
Contactos e Locais
Contato de estudo
- Nome: Patients Contact: Trial Recruitment
- Número de telefone: 1-888-756-8657
- E-mail: trialrecruitment@ultragenyx.com
Estude backup de contato
- Nome: HCPs Contact: Medical Information
- Número de telefone: 1-888-756-8657
- E-mail: medinfo@ultragenyx.com
Locais de estudo
-
-
South Australia
-
North Adelaide, South Australia, Austrália, 5006
- Concluído
- Women's and Children's Hospital
-
-
-
-
-
Santiago de Compostela, Espanha, 15706
- Recrutamento
- Hospital Clínico Universitario de Santiago
-
Contato:
- Eines Monteagudo, MD
- E-mail: eines.monteagudo.vilavedra@sergas.es
-
Investigador principal:
- Maria Luz Couce, MD
-
Contato:
- Beatriz Martín López-Pardo, MD
- E-mail: beatriz.martin.lopezpardo@sergas.es
-
-
Barcelona
-
Barcelona, Barcelona, Espanha, 08035
- Recrutamento
- Vall d'Hebron Barcelona Hospital Campus
-
Investigador principal:
- Mireia del Toro, MD
-
Contato:
- Mireia del Toro, MD
- E-mail: mireia.deltoro@vallhebron.cat
-
-
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43205
- Concluído
- Nationwide Children's Hospital
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15224
- Concluído
- Children's Hospital of Pittsburgh
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Diagnosis of MPS IIIA confirmed by the following methods:
- No detectable or significantly reduced SGSH enzyme activity by leukocyte assay, and
- Genomic DNA analysis demonstrating homozygous or compound heterozygous mutations in the SGSH gene (based upon review of documented results from a qualified laboratory, and with confirmation with Medical Monitor)
-
Age:
- For Cohort 1-3: From birth (participating sites in USA and Australia) OR 6 months (participating sites in Spain) to 2 years of age with no BSITD-III Cognitive Development Quotient (DQ) requirement, or older than 2 years with a BSITD-III Cognitive DQ of 60 or above (participating sites globally).
- For Cohort 4 (participating sites in Spain): 3 months to ≤ 2 years of age with no BSITD-III Cognitive DQ requirement or > 2 years of age with a BSITD-III Cognitive DQ ≥ 60 (n = up to 6). Up to 2 additional subjects > 2 years and ≤ 5 years of age with a BSITD-III Cognitive DQ < 60 may also be enrolled. •Subjects must be ≥ 6 months of age before UX111 administration. However, subjects may be consented and initiate relevant Screening Procedures and IM treatment < 6 months of age. Refer to Section 8.2 for relevant screening procedures •For children ≤ 24 months chronological age who were born prematurely, defined as born at < 36 weeks gestational age, the corrected gestational age must be used for determining inclusion •The BSITD-III Cognitive DQ is assessed during the onsite Screening visit, for subjects who require it •The age of the child on the date of the Screening BSITD-III assessment is used to determine the requirement for the BSITD-III Cognitive DQ score.
-
Cohort 4 only: Vaccination status based on age according to country-specific guidelines that is up to date 30 days prior to Enrollment as verified by documentation from the subject's primary care physician, and willing to defer vaccines through 6 months after completion of the subject's IM medication, or longer per Principal Investigator (PI) judgment. Emergency use authorization or conditional marketing authorization of coronavirus disease (COVID) vaccines is included unless there is an accepted medical exemption.
Exclusion Criteria:
-
Inability to participate in the clinical evaluation as determined by PI
-
Cohorts 1 to 3 only: Identification of two nonsense or null variants on genetic testing of the SGSH gene (based upon review of documented results from a qualified laboratory, and with confirmation with Medical Monitor)
-
At least one S298P mutation in the SGSH gene (based upon review of documented results from a qualified laboratory, and with confirmation with Medical Monitor)
-
Has evidence of an attenuated phenotype of MPS IIIA, in the judgement of the PI
-
Presence of a concomitant medical condition that precludes lumbar puncture or use of anesthetics
-
Active viral infection based on clinical observations
-
Concomitant illness or requirement for chronic drug treatment that in the opinion of the PI creates unnecessary risks for gene transfer or precludes the child from participating in the protocol assessments and follow up
-
Cohorts 1 to 3 only: Subjects with total anti-AAV9 antibody titers ≥ 1:100 equivalent to a positive screen as determined by ELISA binding assay in serum
-
Cohorts 1-3 only: Subjects with a positive response for the enzyme-linked immunosorbent spot assay (ELISpot) for T-cell responses to AAV9
-
Cohorts 1-3 only: Serology consistent with exposure to human immunodeficiency virus (HIV), or serology consistent with active hepatitis B or C infection, Cohort 4: Current clinically significant infections (including any requiring systemic treatment including, but not limited to, HIV; hepatitis A, B, or C; varicella zosters virus; human T-cell lymphotropic virus type 1 [HTLV-1]; tuberculosis; or COVID-19) that would interfere with participation in the study.
-
Bleeding disorder or any other medical condition or circumstance in which a lumbar puncture (for collection of CSF) is contraindicated according to local institutional policy
-
Visual, hearing, or other impairment sufficient to preclude cooperation with neurodevelopmental testing
-
Uncontrolled seizure disorder
-
Any item (braces, etc.) or circumstance that would exclude the subject from being able to undergo MRI according to local institutional policy
-
Any other situation that precludes the subject from undergoing procedures required in this study
-
Subjects with cardiomyopathy or significant congenital heart abnormalities
-
The presence of significant non-MPS IlIA related CNS impairment or behavioral disturbances that would confound the scientific rigor or interpretation of results of the study
-
Cohorts 1-3: Abnormal laboratory values Grade 2 or higher as defined in common terminology criteria for adverse events (CTCAE) v4.03 for gamma-glutamyl transferase (GGT), total bilirubin, creatinine, hemoglobin, white blood cell (WBC) count, platelet count, prothrombin time (PT) and activated partial thromboplastin time (aPTT), Cohort 4: Any of the following abnormal laboratory values from screening assessment:
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT), GGT, and/or alkaline phosphatase ≥ 2 × upper limit of normal (ULN) and/or total bilirubin > 1.5 × ULN
- Anemia (hemoglobin < 10 g/dL)
- Leukopenia or leukocytosis (total WBC count < 3,000/mm3 and > 15,000/mm3 respectively)
- Abnormal absolute neutrophil count (ANC) of < 1000/mm3
- Platelet count < 100,000/mm3
- Coagulopathy (international normalized ratio [INR] > 1.5) or aPTT > 40 seconds
- Renal impairment, defined as estimated glomerular filtration rate (eGFR) below the lower limit of normal (age and sex appropriate) based on Bedside Schwartz equation
-
Female of childbearing potential who is pregnant or demonstrates a positive urine or bhCG result at screening assessment (if applicable)
-
Cohorts 1-3: Any vaccination with viral attenuated vaccines less than 30 days prior to the scheduled date of treatment (and use of prednisolone)
-
Previous treatment by hematopoietic stem cell transplantation
-
Previous participation in a gene/cell therapy or enzyme replacement therapy (ERT) clinical trial
Cohort 4 only:
- Known hypersensitivity, that in the judgment of the PI, places the subject at increased risk for adverse effects.
- Unwilling to avoid consumption of grapefruit juice and the use of strong inhibitors of CYP3A4 and/or P-gp (eg, ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, or clarithromycin), strong inducers of CYP3A4 and/or P-gp (eg, rifampin, rifabutin, phenobarbital, carbamazepine, or phenytoin), and St. John's Wort from 30 days prior to Screening through completion of the IM regimen.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Cohort 1 Low Dose
Dose of 0.5 X 10^13 vg/kg |
Self-complementary adeno-associated virus serotype 9 carrying the human SGSH gene under the control of a U1a promoter (scAAV9.U1a.hSGSH) will be delivered one time through a venous catheter inserted into a peripheral limb vein.
Outros nomes:
The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IM therapy. Not all participants may receive adjuvant IM therapy. |
|
Experimental: Cohort 2 Mid Dose
Dose of 1 X 10^13 vg/kg |
Self-complementary adeno-associated virus serotype 9 carrying the human SGSH gene under the control of a U1a promoter (scAAV9.U1a.hSGSH) will be delivered one time through a venous catheter inserted into a peripheral limb vein.
Outros nomes:
The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IM therapy. Not all participants may receive adjuvant IM therapy. |
|
Experimental: Cohort 3 High Dose
Dose of 3 X 10^13 vg/kg |
Self-complementary adeno-associated virus serotype 9 carrying the human SGSH gene under the control of a U1a promoter (scAAV9.U1a.hSGSH) will be delivered one time through a venous catheter inserted into a peripheral limb vein.
Outros nomes:
The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IM therapy. Not all participants may receive adjuvant IM therapy. |
|
Experimental: Cohort 4 High Dose (Spain Only)
Dose of 3 X 10^13 vg/kg |
Self-complementary adeno-associated virus serotype 9 carrying the human SGSH gene under the control of a U1a promoter (scAAV9.U1a.hSGSH) will be delivered one time through a venous catheter inserted into a peripheral limb vein.
Outros nomes:
The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IM therapy. Not all participants may receive adjuvant IM therapy. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Cerebrospinal Fluid (CSF) Heparan Sulfate (HS) (Disaccharide) Exposure
Prazo: Up to Month 24 Visit
|
Exposure is defined as the time-normalized area under the curve (AUC) of the percentage reduction from baseline. |
Up to Month 24 Visit
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Alteração percentual da linha de base no LCR HS
Prazo: Linha de base, visita até o mês 24
|
Linha de base, visita até o mês 24
|
|
|
Alteração percentual da linha de base no volume cortical total
Prazo: Linha de base, visita até o mês 24
|
Linha de base, visita até o mês 24
|
|
|
Escalas Bayley de Desenvolvimento Infantil e Infantil - Terceira Edição (BSITD-III) Pontuação Cognitiva Bruta ao Longo do Tempo
Prazo: Visita até o 24º mês
|
Visita até o 24º mês
|
|
|
Pontuação bruta de comunicação receptiva BSITD-III ao longo do tempo
Prazo: Visita até o 24º mês
|
Visita até o 24º mês
|
|
|
Pontuação bruta de comunicação expressiva BSITD-III ao longo do tempo
Prazo: Visita até o 24º mês
|
Visita até o 24º mês
|
|
|
CSF Ganglioside Type 2 (GM2) Exposure
Prazo: Up to Month 24 Visit
|
Exposure is defined as the time-normalized area under the curve (AUC) of the percentage change from baseline. |
Up to Month 24 Visit
|
|
CSF Ganglioside Type 3 (GM3) Exposure
Prazo: Up to Month 24 Visit
|
Exposure is defined as the time-normalized area under the curve (AUC) of the percentage change from baseline. |
Up to Month 24 Visit
|
Outras medidas de resultado
Medida de resultado |
Prazo |
|---|---|
|
Número de participantes com eventos adversos emergentes do tratamento e eventos adversos graves emergentes do tratamento
Prazo: Visita até o 24º mês
|
Visita até o 24º mês
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Diretor de estudo: Medical Director, Ultragenyx Pharmaceutical Inc
Publicações e links úteis
Publicações Gerais
- Fu H, Meadows AS, Pineda RJ, Kunkler KL, Truxal KV, McBride KL, Flanigan KM, McCarty DM. Differential Prevalence of Antibodies Against Adeno-Associated Virus in Healthy Children and Patients with Mucopolysaccharidosis III: Perspective for AAV-Mediated Gene Therapy. Hum Gene Ther Clin Dev. 2017 Dec;28(4):187-196. doi: 10.1089/humc.2017.109. Epub 2017 Oct 24.
- McCurdy VJ, Johnson AK, Gray-Edwards HL, Randle AN, Bradbury AM, Morrison NE, Hwang M, Baker HJ, Cox NR, Sena-Esteves M, Martin DR. Therapeutic benefit after intracranial gene therapy delivered during the symptomatic stage in a feline model of Sandhoff disease. Gene Ther. 2021 Apr;28(3-4):142-154. doi: 10.1038/s41434-020-00190-1. Epub 2020 Sep 3.
- Fu H, Cataldi MP, Ware TA, Zaraspe K, Meadows AS, Murrey DA, McCarty DM. Functional correction of neurological and somatic disorders at later stages of disease in MPS IIIA mice by systemic scAAV9-hSGSH gene delivery. Mol Ther Methods Clin Dev. 2016 Jun 8;3:16036. doi: 10.1038/mtm.2016.36. eCollection 2016.
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimado)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Metabolismo, Erros Inatos
- Doenças Genéticas, Congênitas
- Doenças Metabólicas
- Doenças do Tecido Conjuntivo
- Metabolismo de Carboidratos, Erros Inatos
- Doenças de Armazenamento Lisossomal
- Mucinoses
- Mucopolissacaridoses
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Doenças Nutricionais e Metabólicas
- Doenças da Pele e do Tecido Conjuntivo
- Mucopolissacaridose III
- Terapêutica
Outros números de identificação do estudo
- ABT-001
- UX111-CL301 (Outro identificador: Ultragenyx Pharmaceutical Inc)
- 2015-003904-21 (Número EudraCT)
- 2023-510032-37-00 (Ctis)
- 2023 (Concessão/Contrato do NIH dos EUA)
- 2015 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .